Medxy AI – Page 31

Beyond the Pill: Why Elexacaftor/Tezacaftor/Ivacaftor Alone Is Not Enough for Peak Physical Fitness in Cystic Fibrosis

By MedXY 02/04/2026

An Italian multicentric study reveals that while ETI therapy significantly improves several health markers in Cystic Fibrosis patients, its impact on peak aerobic capacity is modest, emphasizing the indispensable need for structured physical exercise alongside pharmacological treatment.

Cardiology General Surgery news

Anatomically Directed HGF Gene Therapy Significantly Accelerates Ulcer Healing in Chronic Limb-Threatening Ischemia: Insights from the LEGenD-1 Trial

By MedXY 02/04/2026

The LEGenD-1 trial demonstrates that intramuscular HGF gene therapy (AMG0001) significantly reduces healing time for neuroischemic ulcers in patients with moderate chronic limb-threatening ischemia, offering a potential nonsurgical therapeutic breakthrough for an underserved patient population.

Diabetes & Endocrinology Internal Medicine news

Signaling-Biased Dual GLP-1/GIP Agonist CT-388 Achieves Remarkable 8% Weight Loss in Just Four Weeks

By MedXY 02/04/2026

A Phase 1 study of CT-388, a novel signaling-biased dual GLP-1/GIP receptor agonist, demonstrated up to 8% body weight reduction in 28 days with a safety profile consistent with existing incretin therapies, signaling a potential shift in metabolic disease management.

Diabetes & Endocrinology Neurology news

Liraglutide and Alzheimer’s Disease: Can GLP-1 Agonists Bridge the Metabolic-Cognitive Gap?

By MedXY 02/04/2026

The Phase 2b ELAD trial investigated liraglutide's efficacy in mild-to-moderate Alzheimer's disease. While it failed its primary metabolic endpoint, significant improvements in executive function suggest a nuanced role for GLP-1 agonists in neuroprotection and cognitive preservation.

Cardiology Internal Medicine news

Beyond HDL-C: How Macronutrient Shifts Reshape HDL Subspecies to Reduce Coronary Risk

By MedXY 02/04/2026

The OmniHeart trial reveals that replacing dietary carbohydrates with unsaturated fats or protein favorably modifies 15 minor protein-based HDL subspecies, shifting the proteomic profile toward lower coronary heart disease risk, independent of total HDL-C levels.

Diabetes & Endocrinology Internal Medicine news

Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control

By MedXY 02/04/2026

This Phase 1 study reveals that LY3537021, a long-acting GIPR agonist, independently drives significant weight loss and improves glucose regulation with a favorable safety profile and a 12-day half-life, clarifying the distinct therapeutic role of GIP in metabolic disease management.

Diabetes & Endocrinology news Psychiatry

Addressing the Human Element: Why Psychological Barriers and Educational Gaps Limit the Efficacy of Diabetes Decision Support Systems

By MedXY 02/04/2026

A randomized trial reveals that while automated decision support systems show marginal overall glycemic benefits in type 1 diabetes, personalized informative feedback significantly aids users with lower baseline knowledge. Success depends heavily on addressing diabetes-related distress and hypoglycemia worry.

Diabetes & Endocrinology Nephrology news

Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes

By MedXY 02/04/2026

A pilot study shows that combining GLP-1 analogues and SGLT2 inhibitors with lifestyle changes significantly reduces body weight and albuminuria in overweight Type 1 diabetes patients with CKD, though glycemic and blood pressure improvements remain elusive.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream strategy for rhythm control.

Diabetes & Endocrinology news

Predicting the Clock: Machine Learning Refines Insulin Timing in Gestational Diabetes Management

By MedXY 02/04/2026

A secondary analysis of the EMERGE trial reveals that Random Survival Forest models utilizing early glycemic data can accurately predict the time to insulin initiation in women with gestational diabetes, offering a roadmap for personalized metabolic management and improved maternal-fetal outcomes.

Diabetes & Endocrinology news Public Health

The Sweet Tooth Trial: Evidence Challenges the Assumption That Lowering Exposure Reduces Sweet Taste Liking

By MedXY 02/04/2026

A 6-month randomized controlled trial reveals that varying dietary sweet taste exposure does not alter sweet taste liking, energy intake, or body weight, questioning the efficacy of public health recommendations to reduce sweet exposure for palate retraining.

Diabetes & Endocrinology Internal Medicine news

Once-Weekly Insulin GZR4: A Potential Paradigm Shift in Basal Insulin Therapy for Type 2 Diabetes

By MedXY 02/04/2026

A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable CAD: The FAME 2 Trial

By MedXY 02/04/2026

The 11-year FAME 2 trial results confirm that FFR-guided PCI significantly improves outcomes for stable CAD patients with functionally significant lesions, primarily by reducing urgent revascularizations, reinforcing the importance of physiological assessment in revascularization decisions.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.

Diabetes & Endocrinology Internal Medicine news

Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes

By MedXY 02/04/2026

A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.

Cardiology news

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

By MedXY 02/04/2026

The REPEAT-QFR study reveals modest agreement between in-procedure and core laboratory quantitative flow ratio (QFR) measurements, suggesting that angiographic quality and user adherence significantly impact diagnostic accuracy.

Diabetes & Endocrinology news Public Health

Challenging Public Health Dogma: Six Months of Low Sweet Taste Exposure Fails to Shift Preference or Weight

By MedXY 02/04/2026

The Sweet Tooth Trial reveals that reducing dietary sweet exposure for six months does not decrease sweet taste liking, calorie intake, or weight, questioning the efficacy of current public health strategies centered solely on reducing sweet-tasting food exposure.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease

By MedXY 02/04/2026

An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable win ratio of 1.25.

Cardiology Diabetes & Endocrinology news

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

By MedXY 02/04/2026

A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible tool for identifying high-risk patients.

Cardiology Diabetes & Endocrinology news

Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study

By MedXY 02/04/2026

This FIELD sub-study reveals that while Haptoglobin 1-1 phenotype combined with low HP levels indicates the lowest CVD risk in Type 2 Diabetes, higher HP levels significantly increase risk, particularly within the HP 1-1 group. Fenofibrate benefits appear independent of HP status.

Beyond the Pill: Why Elexacaftor/Tezacaftor/Ivacaftor Alone Is Not Enough for Peak Physical Fitness in Cystic Fibrosis

Anatomically Directed HGF Gene Therapy Significantly Accelerates Ulcer Healing in Chronic Limb-Threatening Ischemia: Insights from the LEGenD-1 Trial

Signaling-Biased Dual GLP-1/GIP Agonist CT-388 Achieves Remarkable 8% Weight Loss in Just Four Weeks

Liraglutide and Alzheimer’s Disease: Can GLP-1 Agonists Bridge the Metabolic-Cognitive Gap?

Beyond HDL-C: How Macronutrient Shifts Reshape HDL Subspecies to Reduce Coronary Risk

Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control

Addressing the Human Element: Why Psychological Barriers and Educational Gaps Limit the Efficacy of Diabetes Decision Support Systems

Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

Predicting the Clock: Machine Learning Refines Insulin Timing in Gestational Diabetes Management

The Sweet Tooth Trial: Evidence Challenges the Assumption That Lowering Exposure Reduces Sweet Taste Liking

Once-Weekly Insulin GZR4: A Potential Paradigm Shift in Basal Insulin Therapy for Type 2 Diabetes

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable CAD: The FAME 2 Trial

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

Challenging Public Health Dogma: Six Months of Low Sweet Taste Exposure Fails to Shift Preference or Weight

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study

Beyond a Uniform Approach: Data-Driven Phenotyping Reveals High-Risk Clusters in Gestational Diabetes Mellitus

Decoding the Diabetic Heart: Novel Proteomic Signatures of Heart Failure Risk in the ARIC Study

Sex-Specific Risk Stratification in Aortic Regurgitation: Moving Beyond One-Size-Fits-All Thresholds

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management